Actively Recruiting
Phase 2 Study of Elacestrant With or Without Triptorelin Before Surgery in Premenopausal Women With HRHER2- Operable Breast Cancer
Led by SOLTI Breast Cancer Research Group · Updated on 2026-04-24
96
Participants Needed
15
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the biological effects of elacestrant, with or without triptorelin, in premenopausal women diagnosed with primary operable hormone receptor-positiveHER2-negative breast cancer. This phase 2, randomized, open-label, multicenter trial aims to explore how these treatments affect tumor biology before surgery. Eligible patients have tumors larger than 1 cm, with specific markers such as Ki67 between 10-35%, and have not received prior treatment. Participants are randomly assigned to one of two groups in each part of the study. In Part A, women receive either elacestrant alone 400 mg orally once daily for about 30 days or elacestrant combined with triptorelin, an injection given on days 1 and 29 to suppress ovarian function. In Part B, the comparison is between elacestrant alone or tamoxifen 20 mg orally once daily for about 30 days. Blood samples are collected at baseline, mid-treatment, and post-treatment to analyze hormone levels and treatment effects. Optional ultrasounds may assess ovarian and uterine changes in Part B. Surgery follows the treatment period, with tumor samples collected for detailed analysis. During the study, participants undergo regular evaluations including blood tests, imaging, and tissue sample collection to monitor treatment activity and safety. A post-surgery visit occurs within about four weeks after surgery to complete active follow-up. The primary goal is to understand how elacestrant, with or without ovarian suppression, impacts tumor biology in this patient group. Safety and tolerability of the treatments are also closely monitored throughout the trial period.
CONDITIONS
Brief Title
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
Research Team
S
Sara Cano, PhD
J
Juan M Ferrero, PharmD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here